Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more
Location: 1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States | Website: https://www.savarapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
591.1M
52 Wk Range
$1.89 - $4.70
Previous Close
$3.42
Open
$3.44
Volume
1,775,213
Day Range
$3.39 - $3.64
Enterprise Value
474.4M
Cash
146.9M
Avg Qtr Burn
-24.85M
Insider Ownership
5.38%
Institutional Own.
-
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Molgramostim Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | BLA Resubmission |